It refers to a procedure for preparation of drug composition, including: (a) dry combination of at least one active or more precursor chemicals (such as surfactant, polymer, etc.), wherein the active component is a formula compound (I), wherein RA is alifatic (C1-C3),Fluorination (C1-C3),Among them, Rb is f, CH3, CF3, oh, etc.； the preferred compound is 4 - [9-chloro-7 - (2-fluoro-6-methylfenil) - 5h pirimido [5, 4-d] [2] benzazepin-2-il] amine} - 2-methylbenzoato SOD； (b) active starting particles and one or more pre absorbents, such as water, ethanol or acetone； (c) dry the humeda mixture to form dry particles； (d) grind the dry particles to abrasive particles； (E) combine the abrasive particles with shock absorbers, such as sodium carbonate, sodium phosphate, etc., and optionally with one or more excreta；(f) a lubricant is added to compress and form a complete adhesive, or a mixture produced from stage (E) is loaded into a capsule. It also refers to the following pharmacological components: (1) the active component is 1-60%； (2) sodium bicarbonate is 10-80%； (3) microcrystalline cellulose is 10-80%； (4) sodium lactate is 0-5%； (5) sodium sulfate is 0-5%； (6) polyethylene ester is 0-20%； (7) 0-20%. a 20%p/p de croscarmelosa sodicaSE REFIERE A UN PROCEDIMIENTO PARA PREPARAR UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: A) COMBINAR EN SECO AL MENOS UN PRINCIPIO ACTIVO Y OPCIONALMENTE UNO O MAS EXCIPIENTES TAL COMO TENSIOACTIVOS, AGLUTINANTES, ENTRE OTROS, EN DONDE EL PRINCIPIO ACTIVO ES UN COMPUESTO DE FORMULA (I) DONDE Ra ES ALIFATICO(C1-C3), FLUOROALIFATICO(C1-C3), ENTRE OTROS； Rb ES F, CH3, CF3, OH, ENTRE OTROS； SIENDO UN COMPUESTO PREFERIDO EL 4-{[9-CLORO-7-(2-FLUORO-6-METOXIFENIL)-5H-PIRIMIDO[5,4-d][2]BENZAZEPIN-2-IL]AMINO}-2-METOXIBENZOATO DE SODIO； B) GRANULAR EN HUMEDO EL PRINCIPIO ACTIVO Y UNO O MAS EXCIPIENTES EN PRESENCIA DE UN DISOLVENTE TAL COMO AGUA, ETANOL O ACETONA； C) SECAR LA MEZCLA HUMEDA PARA FORMAR GRANULOS SECOS； D) MOLER LOS GRANULOS SECOS PARA
